|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1983-3-11
|
|
pubmed:abstractText |
The results of a pilot multimodality program (surgery + radiotherapy + chemotherapy) are reported in 34 women with advanced stage III and IV adenocarcinoma of the breast. The median relapse-free survival for all patients was 24 months, with 74% of the premenopausal patients and 37% of the postmenopausal alive at five years (P = 0.18). The relapse rate was significantly lower in premenopausal patients when compared to the postmenopausal subgroup. Estrogen receptor status was not predictive for relapse or survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-4790
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:6687399-Adenocarcinoma,
pubmed-meshheading:6687399-Adult,
pubmed-meshheading:6687399-Aged,
pubmed-meshheading:6687399-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6687399-Breast Neoplasms,
pubmed-meshheading:6687399-Cyclophosphamide,
pubmed-meshheading:6687399-Drug Therapy, Combination,
pubmed-meshheading:6687399-Female,
pubmed-meshheading:6687399-Fluorouracil,
pubmed-meshheading:6687399-Follow-Up Studies,
pubmed-meshheading:6687399-Humans,
pubmed-meshheading:6687399-Lymph Node Excision,
pubmed-meshheading:6687399-Mastectomy,
pubmed-meshheading:6687399-Methotrexate,
pubmed-meshheading:6687399-Middle Aged,
pubmed-meshheading:6687399-Neoplasm Staging,
pubmed-meshheading:6687399-Pilot Projects,
pubmed-meshheading:6687399-Radiotherapy,
pubmed-meshheading:6687399-Receptors, Estrogen
|
|
pubmed:year |
1983
|
|
pubmed:articleTitle |
Multimodality therapy of stage III adenocarcinoma of the breast.
|
|
pubmed:publicationType |
Journal Article
|
